Cautionary note regarding forward-looking statements. Statements on this website, including the information set forth as to the future financial or operating performance of the Company, that are not current or historical factual statements may constitute “forward-looking” information within the meaning of applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used on this website, such statements may include, among other language, such words as “may”, “will”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate” and other similar terminology. These statements reflect current expectations, estimates and projections regarding future events and operating performance and speak only as of the date they are made. Readers should not place undue reliance on forward-looking statements and should not rely upon this information as of any other date. These forward-looking statements involve a number of risks and uncertainties including, but not limited to:
- failure to obtain approval from Health Canada for the Company’s semaglutide products and production sites, on the anticipated timeline or at all;
- failure to obtain timely receipt of any other required regulatory approvals;
- ongoing oversight and review of the Company’s products and facilities by regulatory and governmental agencies, including Health Canada and, if applicable, equivalent agencies outside of Canada, which can potentially delay facility inspections and product approvals critical to the Company’s supply continuity and new product launches and/or result in import and export restrictions and the halting of production at the facilities of manufacturing partners;
- ability of the Company’s manufacturing partners to perform to the required specifications of the Company’s products resulting in delays or issues with the Company’s submissions or products;
- ability to obtain components, raw materials or products supplied by third parties and other manufacturing and related supply difficulties, interruptions and delays;
- failure to raise sufficient funding to meet development plans and budgets, satisfy contractual obligations and additional capital needs generally;
- ability to maintain and enforce the protection afforded by any intellectual property or regulatory exclusivity rights;
- the impact of changing conditions and increasing competition in the pharmaceutical and branded consumer health and wellness markets;
- ability to compete against companies that are larger and have greater financial, technical and human resources than the Company, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by competitors;
- reliance on third party contract manufacturers to manufacture the Company’s products on favourable terms;
- risk of patent applications and/or granting of patents of similar products being filed by a competitor;
- the Company’s lack of operating history;
- ability to bring products to market first, or to do so in a timely and cost-efficient manner or in a manner sufficient to grow the Company’s business, replace lost revenue resulting from industry-wide price erosion or take advantage of new technological efficiencies, including artificial intelligence and quantum computing;
- changes in prescription recommendations or behaviours by clinical commissioning groups or other healthcare groups in Canada or any future jurisdictions in which the Company may sell its products;
- risks of litigation, including product liability claims or recalls, sales and marketing practices, intellectual property disputes, anti-trust claims and government investigations generally;
- changes or disruptions in financial markets;
- increased infrastructure, marketing and/or operating costs;
- limits of insurance coverage and uninsurable risk;
- failure to comply with laws and regulations or other regulatory requirements;
- the inability of the Company to retain its key management employees and shortages of skilled personnel and contractors;
- influence of third party stakeholders;
- failures or deficiencies in the Company’s system of internal controls;
- conflicts of interest;
- credit and/or liquidity risks;
- general regulatory environment in which the Company operates, including the areas of taxation, environmental protection, consumer safety and health regulation;
- political instability, hostilities, insurrection or acts of war or terrorism;
- adverse changes in government legislation and regulation;
- general business, economic, competitive, political, regulatory and social uncertainties; and
- the risks involved in the generic pharmaceutical business generally.
The forward-looking statements included on this website are made only as of the date they are made and the Company undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances. There can be no assurance that the projected results can be realized or that actual results will not be materially higher or lower than those projected.